Denali Advisors LLC Acquires New Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Denali Advisors LLC acquired a new stake in Applied Therapeutics, Inc. (NASDAQ:APLT) in the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 33,600 shares of the company’s stock, valued at approximately $228,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new stake in Applied Therapeutics in the fourth quarter valued at about $34,000. Jump Financial LLC acquired a new position in Applied Therapeutics in the fourth quarter valued at approximately $81,000. Citigroup Inc. acquired a new position in Applied Therapeutics in the third quarter valued at approximately $164,000. Worth Venture Partners LLC acquired a new position in Applied Therapeutics in the third quarter valued at approximately $483,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Applied Therapeutics in the third quarter valued at approximately $1,139,000. 98.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Applied Therapeutics

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 61,795 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $266,954.40. Following the sale, the chief executive officer now directly owns 3,756,019 shares of the company’s stock, valued at approximately $16,226,002.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Shoshana Shendelman sold 61,795 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $4.32, for a total value of $266,954.40. Following the transaction, the chief executive officer now owns 3,756,019 shares in the company, valued at $16,226,002.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Leslie D. Funtleyder sold 16,980 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $73,353.60. Following the transaction, the chief financial officer now directly owns 291,441 shares in the company, valued at approximately $1,259,025.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 250,778 shares of company stock valued at $1,066,861. Corporate insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

APLT has been the subject of a number of research reports. UBS Group lifted their target price on Applied Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $12.00 price objective on shares of Applied Therapeutics in a research report on Thursday, April 11th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $11.00.

Applied Therapeutics Price Performance

Shares of NASDAQ APLT traded up $0.03 during trading on Wednesday, hitting $4.38. The company had a trading volume of 556,330 shares, compared to its average volume of 1,599,356. Applied Therapeutics, Inc. has a 52 week low of $1.18 and a 52 week high of $9.39. The business’s 50-day moving average is $4.50 and its 200 day moving average is $4.50.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $10.00 million. On average, research analysts forecast that Applied Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.